| US 7,585,897 B2 | ||
| Modified release formulations of a bupropion salt | ||
| Werner Oberegger, Mississauga (Canada); Fang Zhou, Davie, Fla. (US); Paul Maes, Toronto (Canada); Graham Jackson, Co. Kildare (Ireland); and Mohammad Ashty Saleh, Oakville (Canada) | ||
| Assigned to Biovail Laboratories International S.r.l., St. Michael (Barbados) | ||
| Filed on Jun. 21, 2007, as Appl. No. 11/766,239. | ||
| Application 11/766239 is a continuation of application No. 11/751768, filed on May 22, 2007. | ||
| Application 11/751768 is a continuation of application No. 11/475252, filed on Jun. 27, 2006, granted, now 7,241,805. | ||
| Claims priority of provisional application 60/693906, filed on Jun. 27, 2005. | ||
| Prior Publication US 2008/0081068 A1, Apr. 03, 2008 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 31/135 (2006.01) | ||
| U.S. Cl. 514—649 | 15 Claims |
| 1. A modified release tablet comprising
(a) a core comprising
(i) bupropion hydrobromide in an amount of from 40% to 99% by weight of the tablet dry weight;
(ii) binder in an amount of from 0.25% to 25% by weight of the tablet dry weight; and
(iii) lubricant in an amount of from 0.1% to 6% by weight of the tablet dry weight; and
(b) a control-releasing coat substantially surrounding said core.
|